Bayer shares surge 10% after major legal victory in Roundup cancer litigation: Time to buy?
Bayer AG saw its shares soar by 10% in early German trading following a crucial legal victory concerning its Roundup weedkiller. The surge came after a Philadelphia appeals court ruled in favor of Bayer's Monsanto unit, overturning a previous decision that had found the company liable for cancer risks associated with the herbicide.
Bayer's stock surges after U.S. appeals court strikes down Roundup cancer case
Bayer AG shares surged up to 12% Friday on news it had won a key victory in a U.S. court that should limit its liability in relation to a series of lawsuits over claims that the popular weed killer Roundup causes cancer.
Bayer shares soar 12% after key U.S. legal win against Roundup cancer claims
Bayer shares rose as the company said it scored a legal victory in its suit over claims that exposure to its popular Roundup weed killer led to cancer.
Bayer wins victory in US legal battle against Roundup cancer claims
Bayer won a legal victory in its fight to limit liability from claims that its Roundup weed killer causes cancer, as a U.S. appeals court on Thursday said federal law shields the German company from a lawsuit by a Pennsylvania landscaper.
Bayer: Risks Remain While Business Is Stabilizing
Bayer reported second quarter results and while the results were nothing to get excited about, it was at least not a disappointment. While the Crop Sciences segment is still struggling, Pharmaceuticals and Consumer Health are growing at a solid pace (at least FX adjusted). While the major risks for the business – high debt levels and litigations – remain, the transformation towards a leaner business structure as well as growth and innovation also takes place.
Bayer: Why I'm Careful, But Rate It Buy
I recommend keeping a close eye on Bayer's performance and potential investment opportunities. I have been cautious about Bayer since last article, which discussed the company cutting its dividend. Bayer's stock has since rebounded, with potential for further growth due to positive developments in its pharmaceutical and agricultural divisions.
Bayer (BAYRY) Q2 Earnings In Line, Nubeqa, Kerendia Boost Sales
Bayer's (BAYRY) second-quarter earnings match the consensus estimate. Sales gain from the Pharmaceutical business' strong performance.
Bayer's Monsanto to pay $160 mln to resolve Seattle's PCB contamination lawsuit
Monsanto will pay $160 million to settle a lawsuit by the city of Seattle that accused the unit of Germany's Bayer of polluting the city's drainage system and the local Lower Duwamish River with toxic chemicals known as PCBs.
Australian judge dismisses lawsuit claiming Bayer's Roundup weedkiller causes cancer
An Australian judge said on Thursday it was not proven that an ingredient in Bayer's Roundup weedkiller increases the risk of cancer in users.
Australian court to rule on whether Bayer weedkiller can cause blood cancer
An Australian judge will rule on Thursday on whether Bayer's Roundup weedkiller can cause a type of blood cancer, a closely watched decision that follows some jury verdicts in similar U.S. cases that have found for the plaintiffs.
Bayer (BAYRY) Meets Primary Goal in Nubeqa Expanded-Use Study
Bayer (BAYRY) meets the primary goal in the phase III study evaluating the darolutamide/ADT combo without docetaxel in metastatic hormone-sensitive prostate cancer patients.
Bayer says darolutamide shown to slow prostate cancer progression
Bayer said on Wednesday its drug candidate darolutamide was shown to slow the progression of certain types of prostate cancer in a late-stage trial.
